CCXIU — Churchill Capital XI Share News
0.000.00%
Last trade - 00:00- $632.20m
- $630.94m
Street View: Amgen's ChemoCentryx buy makes sense for robust growth
U.S. STOCKS ON THE MOVE-U.S. homebuilders, AMC Entertainment
U.S. STOCKS ON THE MOVE-Nikola, Coinbase, BridgeBio
Brief: Amgen To Acquire ChemoCentryx For $4 Billion In Cash
ChemoCentryx surges on $3.7 bln buyout deal from Amgen
Amgen to buy ChemoCentryx for $3.7 billion (updated)
Amgen to buy ChemoCentryx in $3.7 billion deal
Brief: ChemoCentryx Inc - Effective As Of June 28, Board Increased Size Of Board From Eight To Nine Members
Brief: ChemoCentryx Announces Appointment Of Jennifer L. Herron To Board As Independent Director
Brief: Chemocentryx Reports Safety Results Available From Ongoing Phase I Trial Of Orally Administered Pd-L1 Inhibitor, Ccx559
U.S. RESEARCH ROUNDUP- Appfolio, Hyatt Hotels, TransDigm Group
U.S. STOCKS ON THE MOVE-GoPro Inc, Humanigen Inc, Redfin Corp
U.S. STOCKS ON THE MOVE-Under Armour, Cigna, Illumina, Nike, FuboTV
U.S. STOCKS ON THE MOVE-Nio Inc, Funko Inc, Cloudflare Inc
ChemoCentryx surges on strong quarterly sales of autoimmune disease drug
Brief: ChemoCentryx Reports Q1 2022 Results
ChemoCentryx Inc reports results for the quarter ended in March - Earnings Summary
ChemoCentryx Inc expected to post a loss of 30 cents a share - Earnings Preview
ChemoCentryx Inc expected to post a loss of 26 cents a share - Earnings Preview